Liquid Biopsy Market Size, Share, and Trends Analysis - Global Industry Forecast, 2026-2036 | NGS, ctDNA, and Early Cancer Detection Propel Market to $18.4 Billion at 10.4% CAGR

Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Liquid Biopsy Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.

The global liquid biopsy market was valued at USD 5.6 billion in 2025 and is projected to increase from an estimated USD 6.8 billion in 2026 to USD 18.4 billion by 2036, registering a CAGR of 10.4% during the forecast period. Market growth is being driven by the rising global cancer burden, increasing demand for minimally invasive diagnostics, expanding adoption of precision oncology, and continued advances in molecular testing technologies.

The report evaluates market performance across biomarker types, sample types, technologies, products, applications, cancer types, end users, and geographic regions. It also examines technological innovation, regulatory and reimbursement conditions, competitive strategies, partnerships, investments, mergers and acquisitions, and long-term growth opportunities within the precision oncology ecosystem.

Market Growth Drivers and Opportunities

Growing demand for early cancer detection and personalized treatment is accelerating the adoption of liquid biopsy solutions. Circulating tumor DNA (ctDNA)-based testing is gaining importance in therapy selection, companion diagnostics, treatment response assessment, minimal residual disease detection, and recurrence monitoring. The increasing use of targeted therapies and immunotherapies is further supporting demand for molecular testing that can identify actionable genetic alterations.

Next -generation sequencing (NGS) represents a major technology segment because it enables comprehensive genomic profiling and simultaneous analysis of multiple biomarkers. Digital PCR is also expected to record strong growth due to its sensitivity, accuracy, and ability to detect low-frequency genetic alterations. PCR-based technologies remain relevant for targeted molecular testing because of their established workflows, reliability, and cost-effectiveness.

Multi-cancer early detection technologies present a significant opportunity for market participants. Expanding clinical research and commercialization initiatives are supporting the development of tests designed to identify cancer-associated signals at earlier stages. Liquid biopsy is also becoming increasingly valuable for ongoing oncology treatment monitoring, allowing clinicians to evaluate therapeutic effectiveness, identify emerging resistance mechanisms, and detect disease progression or recurrence.

Market adoption remains affected by high testing costs, regulatory approval requirements, limited reimbursement coverage, assay performance variability, and technical challenges associated with low-abundance biomarkers. Industry participants are responding through assay innovation, clinical validation, improved sensitivity, strategic collaborations, and development of more cost-effective testing platforms.

Segment Analysis

By biomarker type, the market includes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles/exosomes, cell-free DNA (cfDNA), and other biomarkers. ctDNA represents a significant segment due to its expanding role in identifying mutations, copy number variations, and other molecular changes that support targeted treatment decisions. CTC analysis remains important for prognosis assessment, treatment monitoring, metastatic evaluation, and tumor biology research. Extracellular vesicles and exosomes are emerging areas for biomarker discovery and early cancer detection.

Blood-based liquid biopsy accounts for the largest share by sample type, supported by broad clinical adoption and access to circulating biomarkers such as ctDNA and CTCs. Urine-based testing is gaining attention for potential applications in prostate, bladder, and kidney cancers, while research into other body fluids continues to expand.

By product type, the market is divided into assays and kits, instruments, Software AG , and services. Assays and kits hold a significant position as diagnostic laboratories and healthcare providers adopt clinically validated molecular testing solutions. Software AG and services are becoming more important as demand grows for bioinformatics, genomic data interpretation, and clinical decision-support capabilities.

Major applications include therapy selection and companion diagnostics, cancer screening and early detection, treatment monitoring, recurrence monitoring, and research. Therapy selection and companion diagnostics represent a leading application area, while cancer screening and early detection are expected to generate substantial growth opportunities. Lung cancer remains a major clinical segment because molecular testing is frequently required to identify actionable mutations, particularly when tissue samples are insufficient or difficult to obtain. Applications in breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, and other cancers are also expanding.

Diagnostic laboratories represent a leading end-user segment due to increasing demand for specialized molecular testing services. Hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes are also expanding their use of liquid biopsy technologies for clinical care, drug development, companion diagnostics, clinical trials, and biomarker research.

Regional Market Outlook

North America dominates the liquid biopsy market, supported by advanced healthcare infrastructure, strong precision oncology adoption, substantial research investment, and the presence of leading diagnostic companies. Europe holds a significant market position due to expanding personalized medicine initiatives, cancer research programs, and molecular diagnostics capabilities.

Asia-Pacific is expected to register strong growth as cancer prevalence rises, healthcare infrastructure improves, biotechnology investment increases, and advanced diagnostic technologies gain wider adoption. China, Japan, India, South Korea, and Singapore are key contributors to regional expansion. Latin America and the Middle East & Africa offer emerging opportunities associated with healthcare modernization, improving diagnostic capacity, and greater awareness of early cancer detection.

Competitive Landscape

Competition is intensifying as companies invest in improved biomarker sensitivity, faster turnaround times, clinical validation, broader genomic testing capabilities, and scalable diagnostic platforms. Strategic collaborations among diagnostic companies, pharmaceutical and biotechnology organizations, healthcare providers, research institutions, and laboratories are supporting companion diagnostic development, biomarker validation, clinical trials, and commercialization.

Key companies profiled in the report include Guardant Health, Inc., Foundation Medicine, Inc. ( Roche Diagnostics), Natera, Inc., Exact Sciences Corporation, Bio-Rad Laboratories , Inc., Thermo Fisher Scientific ., Illumina, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., and Laboratory Corporation of America Holdings (Labcorp).

Report Benefits

• Provides market size estimates and growth forecasts through 2036.
• Assesses key drivers, restraints, challenges, technology trends, and emerging opportunities.
• Identifies high-growth biomarkers, sample types, technologies, products, applications, cancer types, end users, and regions.
• Evaluates innovation in Next -generation sequencing, digital PCR, companion diagnostics, and multi-cancer early detection.
• Benchmarks leading companies by product portfolio, clinical evidence, technology capabilities, geographic presence, and strategic initiatives.
• Supports investment planning, product development, partnership evaluation, market entry, and precision oncology strategies.

The report provides actionable market intelligence for diagnostic companies, pharmaceutical and biotechnology organizations, healthcare providers, investors, and research institutions seeking to assess growth opportunities and competitive positioning in the global liquid biopsy market.

For more information about this report visit https://www.researchandmarkets.com/r/8fj4p8

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900